EBV LMP-2A Antibody (15F9): sc-101315

EBV LMP-2A Antibody (15F9) is a rat monoclonal IgG1 antibody that detects the EBV LMP-2A protein of EBV origin by western blotting (WB), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). EBV LMP-2A (15F9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The Epstein-Barr virus (EBV) is a prevalent human herpesvirus that infects a significant portion of the global population, often without causing symptoms; however, EBV is linked to various lymphoid and epithelial malignancies. EBV LMP-2A protein, consisting of 497 amino acids, is characterized by a unique structure, which includes a long N-terminal segment, 12 membrane-spanning domains, and a short C-terminal tail. This structural configuration allows EBV LMP-2A to integrate into the host cell membrane, where EBV LMP-2A plays a pivotal role in modulating cellular signaling pathways. Specifically, EBV LMP-2A interacts with protein tyrosine kinases, activating the phosphatidylinositol 3-kinase (PI3K) pathway, which is essential for promoting cell survival and proliferation. By preventing apoptosis and mimicking B-cell receptor signaling in BCR-negative cells, EBV LMP-2A significantly contributes to the survival of infected cells and the development of EBV-associated tumors, underscoring its importance in oncogenesis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

EBV LMP-2A Antibody (15F9) References:

1. LMP-1's transmembrane domains encode multiple functions required for LMP-1's efficient signaling.  |  Kaykas, A., et al. 2002. J Virol. 76: 11551-60. PMID: 12388716
2. EBV latent membrane protein 2A induces autoreactive B cell activation and TLR hypersensitivity.  |  Wang, H., et al. 2006. J Immunol. 177: 2793-802. PMID: 16920914
3. Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity.  |  Rovedo, M. and Longnecker, R. 2007. J Virol. 81: 84-94. PMID: 17035319
4. Cholesterol is critical for Epstein-Barr virus latent membrane protein 2A trafficking and protein stability.  |  Ikeda, M. and Longnecker, R. 2007. Virology. 360: 461-8. PMID: 17150237
5. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway.  |  Fukuda, M. and Longnecker, R. 2007. J Virol. 81: 9299-306. PMID: 17582000
6. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival.  |  Mancao, C. and Hammerschmidt, W. 2007. Blood. 110: 3715-21. PMID: 17682125
7. Forensic application of Epstein-Barr virus genotype: correlation between viral genotype and geographical area.  |  Ikegaya, H., et al. 2008. J Virol Methods. 147: 78-85. PMID: 17868913
8. Acetylated histone H3 and H4 mark the upregulated LMP2A promoter of Epstein-Barr virus in lymphoid cells.  |  Gerle, B., et al. 2007. J Virol. 81: 13242-7. PMID: 17898065
9. An auto-regulatory loop for EBV LMP2A involves activation of Notch.  |  Anderson, LJ. and Longnecker, R. 2008. Virology. 371: 257-66. PMID: 17980397
10. Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A.  |  Hino, R., et al. 2008. Cancer Res. 68: 1427-35. PMID: 18316606
11. Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lymphoproliferative disorder.  |  Kroll, J., et al. 2011. J Clin Virol. 52: 231-5. PMID: 21900040
12. Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction.  |  Fruehling, S., et al. 1996. J Virol. 70: 6216-26. PMID: 8709248

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-EBV LMP-2A Antibody (15F9) has 7 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

EBV LMP-2A Antibody (15F9) Specifications

Alternate Product Name: Epstein–Barr virus LMP2A

Product Clone Name: 15F9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target: EBV LMP-2A

Epitope Species: EBV

Product Reactivity/Detection: LMP-2A

Species Reactivity/Detection: EBV

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 7 citations in various scientific publications

Available Conjugates/Forms for EBV LMP-2A Antibody (15F9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin